Literature DB >> 27127224

Anatomic or Functional Evaluation as an Initial Test for Stable Coronary Artery Disease: A Propensity Score Analysis.

Gyung-Min Park1, Young-Hak Kim2, Sung-Cheol Yun3, Jung-Min Ahn4, Hyo-In Choi4, Jae-Hyung Roh4, Pil Hyung Lee4, Mineok Chang4, Sang Gyu Lee5, Min-Woo Jo6, Duk-Woo Park4, Soo-Jin Kang4, Seung-Whan Lee4, Cheol Whan Lee4, Dae Hyuk Moon7, Seong-Wook Park4, Seung-Jung Park4.   

Abstract

UNLABELLED: Little data are available to compare the clinical implications of coronary angiography (CAG) or myocardial perfusion imaging (MPI) as an initial evaluation for stable coronary artery disease (CAD).
METHODS: From national health insurance claims data in South Korea, patients aged 18 y or older without a known history of CAD, who underwent CAG or MPI for the diagnosis of stable CAD between 2009 and 2013, were enrolled. Patients were divided into CAG (n = 117,134) and MPI (n = 19,932) groups. The primary endpoint, defined as a composite of all-cause death and myocardial infarction, was compared by a propensity score analysis between the 2 groups.
RESULTS: There was a significant increase (39%) in the annual rate of CAG from 23,985 in 2009-2010 to 33,373 in 2012-2013. However, a substantial reduction (41%) in the annual MPI rate was also noted from 6,389 in 2009-2010 to 3,790 in 2012-2013. During the follow-up period (median, 2.4 y; interquartile range, 1.5-3.5), coronary revascularization was more frequently performed in the CAG group (adjusted hazard ratio [aHR] of CAG, 24.15; 95% confidence interval [CI], 19.66-29.68; P < 0.001). However, the incidence of the primary endpoint was significantly higher in the CAG group (aHR, 1.26; 95% CI, 1.17-1.36; P < 0.001). The individual endpoints of death (aHR, 1.16; 95% CI, 1.06-1.25; P = 0.001) and myocardial infarction (aHR, 1.95; 95% CI, 1.60-2.36; P < 0.001) were also higher in the CAG group.
CONCLUSION: As an initial diagnostic test in patients with stable CAD, MPI is associated with a better clinical outcomes than CAG.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  coronary angiography; coronary artery disease; diagnostic test; myocardial perfusion imaging

Mesh:

Year:  2016        PMID: 27127224     DOI: 10.2967/jnumed.115.169318

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

Review 1.  KSNM60 in Cardiology: Regrowth After a Long Pause.

Authors:  Sang-Geon Cho; Eun Jung Kong; Won Jun Kang; Jin Chul Paeng; Hee-Seung Henry Bom; Ihnho Cho
Journal:  Nucl Med Mol Imaging       Date:  2021-06-08

2.  Trends, Characteristics, and Clinical Outcomes of Patients Undergoing Percutaneous Coronary Intervention in Korea between 2011 and 2015.

Authors:  Seungbong Han; Gyung Min Park; Yong Giun Kim; Mahn Won Park; Sung Ho Her; Seung Whan Lee; Young Hak Kim
Journal:  Korean Circ J       Date:  2018-04       Impact factor: 3.243

3.  Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis.

Authors:  Mahn-Won Park; Gyung-Min Park; Seungbong Han; Yujin Yang; Yong-Giun Kim; Jae-Hyung Roh; Hyun Woo Park; Jon Suh; Young-Rak Cho; Ki-Bum Won; Soe Hee Ann; Shin-Jae Kim; Dae-Won Kim; Sung Ho Her; Sang-Gon Lee
Journal:  PLoS One       Date:  2018-12-07       Impact factor: 3.240

4.  Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: Results from a Korean nationwide study.

Authors:  Yujin Yang; Gyung-Min Park; Seungbong Han; Yong-Giun Kim; Jon Suh; Hyun Woo Park; Ki-Bum Won; Soe Hee Ann; Shin-Jae Kim; Dae-Won Kim; Mahn-Won Park; Sung Ho Her; Sang-Gon Lee
Journal:  PLoS One       Date:  2018-12-10       Impact factor: 3.240

5.  Pre-existing depression in patients with coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Jangho Park; Sangwoo Park; Yong-Giun Kim; Soe Hee Ann; Hyun Woo Park; Jon Suh; Jae-Hyung Roh; Young-Rak Cho; Seungbong Han; Gyung-Min Park
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.